Free Trial
NASDAQ:CINGW

Cingulate (CINGW) Stock Price, News & Analysis

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)
Free CINGW Stock Alerts
$0.02
0.00 (0.00%)
(As of 05/2/2024 ET)
Compare
Today's Range
$0.02
▼
$0.02
50-Day Range
$0.01
▼
$0.03
52-Week Range
$0.00
▼
$0.44
Volume
N/A
Average Volume
44,525 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsSEC FilingsSocial Media

About Cingulate

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CINGW Stock Price History

CINGW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive CINGW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:CINGW
CUSIP
N/A
CIK
1862150
Web
www.cingulate.com
Phone
913 942 2300
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Shane J. Schaffer Pharm.D. (Age 49)
    PharmD, CEO & Chairman of the Board
    Comp: $491.96k
  • Dr. Laurie A. Myers M.B.A. (Age 67)
    Ph.D., Executive VP & COO
    Comp: $415.17k
  • Dr. Matthew N. Brams M.D. (Age 60)
    Executive VP & Chief Medical Officer
    Comp: $244.79k
  • Dr. Raul R. Silva M.D. (Age 66)
    Executive VP & Chief Science Officer
  • Thomas Dalton
    Vice President of Investor & Public Relations

Key Competitors

View All Competitors

CINGW Stock Analysis - Frequently Asked Questions

How have CINGW shares performed in 2024?

Cingulate's stock was trading at $0.03 at the beginning of the year. Since then, CINGW stock has decreased by 26.7% and is now trading at $0.0220.
View the best growth stocks for 2024 here.

How do I buy shares of Cingulate?

Shares of CINGW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CINGW) was last updated on 5/3/2024 by MarketBeat.com Staff

From Our Partners
The AI stock to buy right now
StockEarnings
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Could Your Accounts Be Frozen?
Allegiance Gold
Urgent Nvidia Warning
Altimetry
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
$5,000 Gold?
Stansberry Research
READ THIS – If You Missed Out On The AI Boom
Banyan Hill Publishing
Bitcoin Rockets To Record High But Buy THIS Instead
Paradigm Press